Literature DB >> 32205012

Understanding a woman's heart: Lessons from 14 177 women with acute coronary syndrome.

David Roque1, Jorge Ferreira2, Sílvia Monteiro3, Marco Costa3, Victor Gil4.   

Abstract

INTRODUCTION: Coronary artery disease is becoming the leading cause of death in women in Western society. However, the available data shows that women are still underdiagnosed and undertreated with guideline-recommended secondary prevention therapy, leading to a significantly higher rate of in-hospital complications and in-hospital mortality.
OBJECTIVE: The main objective of this work is to assess the approach to acute coronary syndrome (ACS) in Portugal, including form of presentation, in-hospital treatment and in-hospital complications, according to gender and in three different periods.
METHODS: We performed an observational study with retrospective analysis of all patients included between 2002 and 2019 in the Portuguese Registry of Acute Coronary Syndromes (ProACS), a voluntary, observational, prospective, continuous registry of the Portuguese Society of Cardiology and the National Center for Data Collection in Cardiology.
RESULTS: A total of 49 113 patients (34 936 men and 14 177 women) were included. Obesity, hypertension, diabetes (p<0.001 for all) and dyslipidemia (p=0.022) were all more prevalent in women, who were more frequently admitted for non-ST segment elevation ACS (p<0.001), and more frequently presented with atypical symptoms. Women had more time until needle and until reperfusion, which is less accessible to this gender (p<0.001). During hospitalization, women had a significantly higher risk of in-hospital mortality (OR 1.94 [1.78-2.12], p<0.001), major bleeding (OR 1.53 [1.30-1.80], p<0.001), heart failure (OR 1.87 [1.78-1.97], p<0.001), atrial fibrillation (OR 1.55 [1.36-1.77], p<0.001), mechanical complications (OR 2.12 [1.78-2.53], p<0.001), cardiogenic shock (OR 1.71 [1.57-1.87], p<0.001) and stroke (OR 2.15 [1.76-2.62], p<0.001). Women were more likely to have a normal coronary angiogram or coronary lesions with <50% luminal stenosis (p<0.001 for both), and thus a final diagnosis other than ACS. Both during hospitalization and at hospital discharge, women were less likely to receive guideline-recommended secondary prevention therapy.
CONCLUSION: In women admitted for ACS, revascularization strategies are still underused, as is guideline-recommended secondary prevention therapy, which may explain their higher incidence of in-hospital complications and higher unadjusted mortality.
Copyright © 2020 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Acute coronary syndrome; Mulher; Síndroma coronária aguda; Women

Mesh:

Substances:

Year:  2020        PMID: 32205012     DOI: 10.1016/j.repc.2020.03.002

Source DB:  PubMed          Journal:  Rev Port Cardiol        ISSN: 0870-2551            Impact factor:   1.374


  3 in total

1.  Sex-Specific Impact of Different Obesity/Metabolic Phenotypes on Long-Term Cardiovascular Outcomes in Acute Coronary Syndrome Patients.

Authors:  Egidio Imbalzano; Giuseppina T Russo; Annalisa Giandalia; Angela Sciacqua; Luana Orlando; Vincenzo Russo; Maria Perticone; Arrigo F G Cicero; Antonio Giovanni Versace; Pierpaolo Di Micco; Vincenzo Antonio Ciconte; Giuseppe Dattilo; Giovanni Squadrito; Marco Vatrano
Journal:  Biomedicines       Date:  2022-02-10

2.  Effect of PCI Standardized Telephone Follow-Up Service Mode on Out-of-Hospital Complications, Rehospitalization Rate, and Quality of Life of Discharged Patients with Acute Coronary Syndrome after PCI.

Authors:  Luyan Zhang; Yaling Tian; Hong Ren; Aihong Zhu; Li Dong; Xiuqin Wang; Xiaoyu Han
Journal:  Comput Math Methods Med       Date:  2022-07-21       Impact factor: 2.809

3.  2020 Top 10 Original Articles in the Arquivos Brasileiros de Cardiologia and the Revista Portuguesa de Cardiologia.

Authors:  Ricardo Fontes-Carvalho; Gláucia Maria Moraes de Oliveira; Nuno Cardim; Carlos Eduardo Rochitte
Journal:  Arq Bras Cardiol       Date:  2021-06       Impact factor: 2.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.